Zobrazeno 1 - 10
of 174
pro vyhledávání: '"Murali, Gopalakrishnan"'
Autor:
Murali Gopalakrishnan
Publikováno v:
Asian Journal of Comparative Politics. 5:400-415
The acceptance of refugees and internally displaced persons represents the altruism of the countries of South Asia, which has witnessed the phenomenon of displaced persons since the early 19th century. The refugee phenomenon has a causal nature and w
Autor:
Arthur L. Nikkel, Marian T. Namovic, D. L. Widomski, Diana L. Donnelly-Roberts, Steve McGaraughty, Zhi Su, Laura Leys, Murali Gopalakrishnan
Publikováno v:
Journal of Basic and Clinical Physiology and Pharmacology. 29:281-290
Background:Losartan, a blocker of the angiotensin II type I receptor, is an important part of the standard of care for diabetic nephropathy (DN). The obese ZSF-1 rats display many aspects of the clinical features of human Type II DN. The current stud
Autor:
Anthony M. Giamis, Andrew Goodearl, Christine Grinnell, Kelly J. Doyle, Katherine Salte, Victor Sun, Todd B. Cole, Murali Gopalakrishnan, L. Olson, Susan E. Lacy, Meha Chhaya, Yanping Luo, Steve McGaraughty, Arthur L. Nikkel, Rachel Davis-Taber, Chang Z. Zhu, Gregory M. Preston
Publikováno v:
Journal of the American Society of Nephrology. 28:3616-3626
Targeted delivery of a therapeutic agent to a site of pathology to ameliorate disease while limiting exposure at undesired tissues is an aspirational treatment scenario. Targeting diseased kidneys for pharmacologic treatment has had limited success.
Autor:
Arthur L. Nikkel, Ji Ma, L. Olson, Sujatha M. Gopalakrishnan, Kelly J. Doyle, Vivek C. Abraham, D. L. Widomski, Steve McGaraughty, Brent Putman, Murali Gopalakrishnan, Laura Leys, Chang Z. Zhu, Steve D. Pratt, Zhi Su, Chih-Hung Lee, K. Salte
Publikováno v:
European Journal of Pharmacology. 788:1-11
Adenosine (ADO) is an important regulatory purine nucleoside that accumulates at sites of inflammation and tissue injury including in diseases associated with renal pathology. Endogenous levels of ADO may be increased by inhibiting the ADO-metabolizi
Autor:
Diana L. Donnelly-Roberts, Arthur L. Nikkel, Chang Z. Zhu, Steve McGaraughty, Kelly J. Doyle, Murali Gopalakrishnan, Marian T. Namovic, K. Salte, Lauren Olsen, D. L. Widomski, Zhi Su
Publikováno v:
Journal of pharmacological and toxicological methods. 94(Pt 1)
Introduction The adenine model of kidney disease typically involves dietary delivery of adenine over several weeks. This model can be variable in its disease progression and can result in significant mortality. In the current study, the amount of ade
Autor:
Steve, McGaraughty, Rachel A, Davis-Taber, Chang Z, Zhu, Todd B, Cole, Arthur L, Nikkel, Meha, Chhaya, Kelly J, Doyle, Lauren M, Olson, Gregory M, Preston, Christine M, Grinnell, Katherine M, Salte, Anthony M, Giamis, Yanping, Luo, Victor, Sun, Andrew D, Goodearl, Murali, Gopalakrishnan, Susan E, Lacy
Publikováno v:
Journal of the American Society of Nephrology : JASN. 28(12)
Targeted delivery of a therapeutic agent to a site of pathology to ameliorate disease while limiting exposure at undesired tissues is an aspirational treatment scenario. Targeting diseased kidneys for pharmacologic treatment has had limited success.
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 343:736-745
Nicotinic acetylcholine receptor (nAChR) agonists improve sensory gating deficits in animal models and schizophrenic patients. The aim of this study was to determine whether the novel and selective α7 nAChR full agonist 5-(6-[(3R)-1-azabicyclo[2.2.2
Autor:
Jennifer M. Frost, Jianguo Ji, William H. Bunnelle, Tao Li, Murali Gopalakrishnan, David J. Anderson, Kevin B. Sippy, Carol S. Surowy, Michael Meyer, Clark A. Briggs, Michael R. Schrimpf
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 22:1633-1638
The well-known interferon-inducer tilorone was found to possess potent affinity for the agonist site of the α7 neuronal nicotinic receptor (K(i)=56 nM). SAR investigations determined that both basic sidechains are essential for potent activity, howe
Autor:
Sujatha M. Gopalakrishnan, Jens Halvard Grønlien, David J. Burns, John Malysz, Usha Warrior, Betsy M. Philip, David J. Anderson, Murali Gopalakrishnan
Publikováno v:
ASSAY and Drug Development Technologies. 9:635-645
α7 nicotinic acetylcholine receptors (nAChRs) are characterized by relatively low ACh sensitivity, rapid activation, and fast desensitization kinetics. ACh/agonist evoked currents at the α7 nAChR are transient, and, typically, calcium flux response
Autor:
Chih-Hung Lee, Ann Tovcimak, Michael W. Decker, Gerard B. Fox, Gricelda H. Simler, Prisca Honore, Jordan W. Brown, Chang Z. Zhu, Madhavi Pai, Nathan R. Rustay, Chih-Liang Chin, Chengmin Zhong, Joe Mikusa, Murali Gopalakrishnan, Victoria A. Komater, Donna M. Gauvin, Anita K. Salyers, Scott J. Baker, La Geisha Lewis, Peer B. Jacobson, Erica Gomez, Prasant Chandran
Publikováno v:
Biochemical Pharmacology. 82:967-976
Positive modulation of the neuronal nicotinic acetylcholine receptor (nAChR) α4β2 subtype by selective positive allosteric modulator NS-9283 has shown to potentiate the nAChR agonist ABT-594-induced anti-allodynic activity in preclinical neuropathi